[
  {
    "ts": null,
    "headline": "Strong Product Launches and Upbeat Guidance Could Be a Game Changer for Vertex Pharmaceuticals (VRTX)",
    "summary": "Vertex Pharmaceuticals recently reported strong fiscal second-quarter results, attributing growth to the successful launches of CASGEVY, ALYFTREK, and JOURNAVX, and reaffirmed its full-year revenue forecast of US$11.85 billion to US$12 billion. Management’s planned participation in three major investor conferences in September offers further opportunities to communicate ongoing strategies and maintain engagement with the investment community. We'll look at how Vertex's robust product...",
    "url": "https://finnhub.io/api/news?id=93bce59a895d9541f395de24c91fae905efc9f0dd9c6a4c4a4973d97a44a281a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755857767,
      "headline": "Strong Product Launches and Upbeat Guidance Could Be a Game Changer for Vertex Pharmaceuticals (VRTX)",
      "id": 136476872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals recently reported strong fiscal second-quarter results, attributing growth to the successful launches of CASGEVY, ALYFTREK, and JOURNAVX, and reaffirmed its full-year revenue forecast of US$11.85 billion to US$12 billion. Management’s planned participation in three major investor conferences in September offers further opportunities to communicate ongoing strategies and maintain engagement with the investment community. We'll look at how Vertex's robust product...",
      "url": "https://finnhub.io/api/news?id=93bce59a895d9541f395de24c91fae905efc9f0dd9c6a4c4a4973d97a44a281a"
    }
  }
]